C-erbB-2 expression and prognostic significance in osteosarcoma

Pediatric Blood and Cancer

Volumn 51, Issue 2, 2008, Pages 222-227

  Yalçin, Bilgehan ^a   Gedikoǧlu, Gökhan ^a   Kutluk, Tezer ^a   Varan, Ali ^a   Akyüz, Canan ^a   Büyükpamukçu, Münevver ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

C erbB 2; Osteosarcoma; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CB11;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; DEATH; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SCHOOL CHILD; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR BIOPSY; TUMOR VOLUME; BONE TUMOR; CHEMISTRY; CHILD; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY;

ADOLESCENT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 45549091368     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21576     Document Type: Article

References (27)

1. Link MP, Gebhardt MC, Meyers PA. Osteosarcoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins; 2006. pp 1074-1115.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
3. Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-441.
4. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting summary. Clin Cancer Res 2003;9:5442-5453.
5. Akiyama T, Sudo C, Ogawara H, et al. The product of c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1666.
6. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354.
7. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
8. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-78.
9. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-2788.
10. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100:1936-1942.
11. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-1404.
12. Maitra A, Wanzer D, Weinberg AG, et al. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92:677-683.
13. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40:963-970.
14. Tsai JY, Aviv H, Benevenia J, et al. HER-2/neu and p53 in osteosarcoma: An immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 2004;22:16-24.
15. Somers GR, Ho M, Zielenska M, et al. HER2 Amplification and overexpression is not present in pediatric osteosarcoma. A tissue microarray study. Pediatr Dev Pathol 2005;8:525-532.
16. Vasishta RK, Gupta N, Kakkar N, et al. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma. J Cancer Res Ther 2006;2:20-23.
17. Zhou H, Randall RL, Brothman AR, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
18. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005;41:1349-1361.
19. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001;14:1277-1283.
20. Thomas DG, Giordano TJ, Sanders D, et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002;8:788-793.
21. Akatsuka T, Wada T, Kokai Y, et al. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 2001;60:361-366.
22. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc A 1972;135:185-216.
24. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
25. Hudis CA. Trastuzumab - Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
26. Judson I, In relation to Anninga et al. overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40:924-925.
27. Phase II study of chemotherapy with or without trastuzumab (Herceptin®) in patients with metastatic osteosarcoma. http://cancer.gov/ clinicaltrials/COG-AOST0121.